|
Gamida Cell Ltd (NASDAQ: GMDA) |
|
Gamida Cell Ltd
GMDA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Gamida Cell Ltd growth rates, revenue grew
in I. Quarter 2024 from the same quarter a year ago.
Ranking at No. 263
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.28 %
Gamida Cell Ltd 's net profit decreased by -12.5 % in I. Quarter 2024 year on year, to $20 millions.
• More on GMDA's Growth
|
|
Gamida Cell Ltd current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Gamida Cell Ltd realized cash reduction of $ -0.17 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
0.06 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.91.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
• More on GMDA's Valuation
|
|
|
|
|
Gamida Cell Ltd current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Gamida Cell Ltd realized cash outflow of $ -0.17per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
0.06 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.91.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
• More on GMDA's Valuation
|
|
GMDA's Profitability Comparisons
|
Gamida Cell Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 2824.27 % from 2680.24 % in III. Quarter.
Gamida Cell Ltd net profit margin of 2241.12 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 2 in Healthcare sector and number 13 in S&P 500.
|
|
Gamida Cell Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 2824.27 % from 2680.24 % in III. Quarter.
Gamida Cell Ltd net profit margin of 2241.12 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 2 in Healthcare sector and number 13 in S&P 500.
• More on GMDA's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com